Sunday, December 20, 2009

Parasite Evades Death By Promoting Host Cell Survival

The parasite Trypanosoma cruzi (or T. cruzi), which causes Chagas' disease, will go to great lengths to evade death once it has infected human host cells, researchers have discovered. In a study published in the November 17 online issue of Science Signaling, the researchers describe how a protein called parasite-derived neurotrophic factor (PDNF) prolongs the life of the T. cruzi parasite by activating anti-apoptotic (or anti-cell-death) molecules in the host cell. These protective mechanisms help to explain how host cells continue to survive despite being exploited by T. cruzi parasites.

"We asked ourselves, 'How is it possible that the host cells stay alive for so long with thousands of T. cruzi parasites consuming the host cell's vital resources?' We discovered that PDNF on the surface of the T. cruzi parasite essentially inhibits cell death signals and activates cell-protective mechanisms, ensuring T. cruzi sufficient time to develop and reproduce in the host cell," says senior author Mercio Perrin, MD, PhD, professor in the pathology department at Tufts University School of Medicine (TUSM) and member of the immunology program faculty at the Sackler School of Graduate Biomedical Sciences at Tufts.

Taking a multi-faceted approach, the researchers used bioinformatics, immunochemistry, intracellular colocalization microscopy, and in vitro enzymatic techniques to study T. cruzi's survival in the host. Perrin and co-author Marina Chuenkova, PhD, a research instructor in the pathology department at TUSM and the Sackler School, demonstrated that PDNF is a substrate and activator of Akt kinase, an enzyme that promotes cell survival by inhibiting "cell death" proteins.

"Further investigation showed that within T. cruzi-infected cells, PDNF also activates increased production of Akt, prolonging its protective effects," says Chuenkova. "Akt is a key regulator of diverse cellular processes, and supports cell survival not only by inhibiting apoptotic molecules, but additionally by increasing nutrient uptake and metabolism," she continued.

"In short, the T. cruzi parasite has a means of establishing life insurance once it has invaded the host. If we can fully understand the mechanisms behind this protection, we can begin to explore ways to undermine it with treatment," said Perrin.

Chagas' disease, typically transmitted to humans by blood-feeding insects, infects an estimated 8 to 11 million people throughout Mexico, and Central and South America. Although it is still rare in the United States, according to the Centers for Disease Control and Prevention (CDC), there are 300,000 people with Chagas' disease living in the United States, most of whom acquired the disease while living in other countries.

The acute phase of Chagas' disease can result in fever or swelling at the site of the insect bite, but many people do not experience symptoms at all. If left untreated, the disease enters an indeterminate phase in which no symptoms are present. During this phase, many people are not aware that they are infected, but approximately 30 percent will eventually develop life-threatening complications of the disease, including enlargement of the digestive tract and/or heart.

This study was funded by grants from the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health.

Chuenkova MV and PereiraPerrin M. Science Signaling. 2009. (November 17); 2(97), ra74. "Trypanosoma cruzi targets Akt in host cells as an intracellular antiapoptotic strategy." Published online November 17, 2009, doi: 10.1126/scisignal.2000374

About Tufts University School of Medicine

Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. The Sackler School undertakes research that is consistently rated among the highest in the nation for its impact on the advancement of medical science.

Source: Tufts University

Saturday, December 19, 2009

Tiny RNA Has Big Impact On Lung Cancer Tumors

Researchers from Yale University and Mirna Therapeutics, Inc., reversed the growth of lung tumors in mice using a naturally occurring tumor suppressor microRNA. The study reveals that a tiny bit of RNA may one day play a big role in cancer treatment, and provides hope for future patients battling one of the most prevalent and difficult to treat cancers.

"This is the first time anybody has shown a positive effect of microRNAs in shrinking lung cancer," said Frank Slack, Ph.D., co-senior author of the paper, researcher at the Yale Cancer Center and professor of molecular, cellular & developmental biology.

The tumors in mice with non-small cell lung cancer shrank after the Yale team delivered an intranasal dose containing a type of micro-RNA called let-7, the authors reported in the Dec. 7 issue of the journal Oncogene. MicroRNAs are small bits of genetic material most often associated with transmission of information encoded in DNA. However in the past decade microRNAs have been shown to play crucial roles in gene regulation and/or gene silencing

The Yale team also found that mice without let-7 developed cancer, supporting their hypothesis that the microRNA acts as a tumor suppressor. The tumors in mice that received let-7 were not eliminated, but reduced by 66 percent, the study showed. The team is currently studying whether let-7 therapy in combination with chemotherapy and radiation can induce full remission.

Slack noted let-7 is absent in many cancers and acts upon a gene known to play a role in about a quarter of all human cancers.

"We hope it will be valuable in the treatment of many other forms of cancer," he said.

The research was conducted as part of collaboration between Yale and Mirna Therapeutics Inc, a biotechnology company in Austin, Texas. Joanne B. Weidhaas, MD/Ph.D. of Yale and Andreas G. Bader, Ph.D. of Mirna were co-senior authors of the paper. Other Yale authors on the paper are first author Phong Trang, Pedro P. Medina and Robert Homer; other Mirna authors are Jason F. Wiggins, Lynnsie Ruffino, Kevin Kelnar, Michael Omotola and David Brown, Ph.D.

Funding for the work came from the National Institutes of Health, Connecticut Department of Health, The Hope Funds for Cancer Research and Mirna Therapeutics, Inc.

Source:
Bill Hathaway
Yale University